Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1 to 10 of 2591 total matches.

Fitusiran (Qfitlia) for Hemophilia A and B

   
The Medical Letter on Drugs and Therapeutics • Jul 07, 2025  (Issue 1732)
disorder (estimated prevalence 1:5000 live male births) characterized by insufficient levels ...
Fitusiran (Qfitlia – Sanofi), a subcutaneously injected, antithrombin-directed, small interfering ribonucleic acid (siRNA), has been approved by the FDA for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients ≥12 years old who have hemophilia A with or without factor VIII inhibitors or hemophilia B with or without factor IX inhibitors. It is the first antithrombin-lowering therapy to become available in the US for treatment of hemophilia.
Med Lett Drugs Ther. 2025 Jul 7;67(1732):110-1   doi:10.58347/tml.2025.1732c |  Show IntroductionHide Introduction

Insect Repellents

   
The Medical Letter on Drugs and Therapeutics • Jul 07, 2025  (Issue 1732)
, pants, and socks and avoiding outdoor activities during peak mosquito-biting times.1 Some insect ...
The Centers for Disease Control and Prevention (CDC) and the Environmental Protection Agency (EPA) recommend using insect repellents to avoid being bitten by mosquitoes, ticks, and other arthropods that transmit disease-causing pathogens. Repellents applied to exposed skin should be used in conjunction with other preventive measures such as wearing long-sleeved shirts, pants, and socks and avoiding outdoor activities during peak mosquito-biting times. Some insect repellents are listed in Table 1.
Med Lett Drugs Ther. 2025 Jul 7;67(1732):105-9   doi:10.58347/tml.2025.1732a |  Show IntroductionHide Introduction

A Blood Test for Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Jul 07, 2025  (Issue 1732)
the Lumipulse G pTau217/ β-Amyloid 1-42 Plasma Ratio (Fujirebio), a blood-based diagnostic test, for early ...
The FDA has cleared the Lumipulse G pTau217/ β-Amyloid 1-42 Plasma Ratio (Fujirebio), a bloodbased diagnostic test, for early detection of amyloid plaque pathology associated with Alzheimer's disease (AD) in adults ≥50 years old who are showing signs and symptoms of the disease. The new assay is the first blood test for amyloid biomarkers to become commercially available in the US. The Lumipulse G β-Amyloid Ratio (1-42/1-40), which measures amyloid biomarkers in cerebrospinal fluid (CSF), was cleared by the FDA in 2022.
Med Lett Drugs Ther. 2025 Jul 7;67(1732):109   doi:10.58347/tml.2025.1732b |  Show IntroductionHide Introduction

In Brief: Dupilumab (Dupixent) for Chronic Spontaneous Urticaria

   
The Medical Letter on Drugs and Therapeutics • Jul 07, 2025  (Issue 1732)
phenotype.1-3 STANDARD TREATMENT ― H1-antihistamines are used for initial treatment of chronic spontaneous ...
The subcutaneously injected interleukin (IL)-4 receptor alpha antagonist dupilumab (Dupixent – Sanofi/Regeneron) has been approved by the FDA for treatment of chronic spontaneous urticaria in patients ≥12 years old who remain symptomatic despite H1-antihistamine treatment. Dupilumab was approved earlier for treatment of asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and chronic obstructive pulmonary disease with an eosinophilic phenotype.
Med Lett Drugs Ther. 2025 Jul 7;67(1732):111-2   doi:10.58347/tml.2025.1732d |  Show IntroductionHide Introduction

In Brief: Hyperthermia with Scopolamine Patches

   
The Medical Letter on Drugs and Therapeutics • Jun 30, 2025  (Issue 5114)
of another drug with anticholinergic effects or exposure to an external heat source.1 The updated label ...
The FDA has required a new warning in the label for the scopolamine transdermal patch (Transderm-Scōp, and generics) about a risk of serious or fatal hyperthermia. Scopolamine, an anticholinergic drug, is FDA-approved for prevention of nausea and vomiting associated with motion sickness or recovery after surgery in adults; it is often used off-label to reduce drooling in children and adolescents with neurologic disorders.
Med Lett Drugs Ther. 2025 Jun 30;67(5114):1   doi:10.58347/tml.2025.5114a |  Show IntroductionHide Introduction

In Brief: Merilog — A NovoLog Biosimilar

   
The Medical Letter on Drugs and Therapeutics • Jun 23, 2025  (Issue 1731)
of an open-label trial (GEMELLI 1) in 597 patients with type 1 or type 2 diabetes. Patients were randomized ...
The FDA has approved Merilog (Sanofi), a biosimilar to rapid-acting insulin aspart (NovoLog), for treatment of patients with type 1 or type 2 diabetes. Merilog is the first rapid-acting insulin biosimilar product to become available in the US.
Med Lett Drugs Ther. 2025 Jun 23;67(1731):104   doi:10.58347/tml.2025.1731c |  Show IntroductionHide Introduction

Sunscreens

   
The Medical Letter on Drugs and Therapeutics • Jun 23, 2025  (Issue 1731)
can cause erythema, photoaging, and skin cancer.1,2 Sunscreens are widely used to reduce these risks ...
Excessive exposure to ultraviolet (UV) radiation can cause erythema, photoaging, and skin cancer. Sunscreens are widely used to reduce these risks, but questions remain about their effectiveness and safety. In 2021, the FDA proposed a rule that would require additional safety studies for some sunscreen active ingredients and mandate better UVA protection in sunscreen products.
Med Lett Drugs Ther. 2025 Jun 23;67(1731):97-102   doi:10.58347/tml.2025.1731a |  Show IntroductionHide Introduction

Vutrisiran (Amvuttra) for Transthyretin Amyloid Cardiomyopathy

   
The Medical Letter on Drugs and Therapeutics • Jun 23, 2025  (Issue 1731)
-type ATTR-CM, which is associated with aging and commonly affects men >60 years old.1,2 ATTR-CM ...
The FDA has approved vutrisiran (Amvuttra – Alnylam), a subcutaneously injected small interfering RNA (siRNA), to reduce cardiovascular hospitalizations, urgent heart failure visits, and cardiovascular death in adults with wild-type or variant transthyretin amyloid cardiomyopathy (ATTR-CM). Vutrisiran is the first siRNA to be approved in the US for this indication; it was approved earlier for treatment of polyneuropathy associated with hereditary transthyretin-mediated amyloidosis.
Med Lett Drugs Ther. 2025 Jun 23;67(1731):102-4   doi:10.58347/tml.2025.1731b |  Show IntroductionHide Introduction

Onapgo ― An Apomorphine Subcutaneous Infusion for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Jun 17, 2025  (Issue 5113)
). Subcutaneously injected apomorphine (Apokyn, and generics) has been available for intermittent use for years.1 ...
Onapgo (Supernus), a solution for continuous subcutaneous infusion containing the dopamine agonist apomorphine, has been approved by the FDA for treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). Subcutaneously injected apomorphine (Apokyn, and generics) has been available for intermittent use for years. Vyalev, a foscarbidopa/foslevodopa solution for subcutaneous infusion, was approved in 2024 for the same indication.
Med Lett Drugs Ther. 2025 Jun 17;67(5113):1-2   doi:10.58347/tml.2025.5113a |  Show IntroductionHide Introduction

In Brief: REMS Removal for Clozapine

   
The Medical Letter on Drugs and Therapeutics • Jun 09, 2025  (Issue 1730)
) program for the second-generation antipsychotic drug clozapine (Clozaril, and others).1 Clozapine ...
The FDA has announced that prescribers, pharmacies, and patients are no longer required to participate in a Risk Evaluation and Mitigation Strategy (REMS) program for the second-generation antipsychotic drug clozapine (Clozaril, and others).
Med Lett Drugs Ther. 2025 Jun 9;67(1730):95   doi:10.58347/tml.2025.1730e |  Show IntroductionHide Introduction